Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro

Satya Narayan, Yan Shi Guo, Courtney Townsend, Pomila Singh

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

In the present study, we characterized specific binding of bombesin (BBS)/gastrin-releasing peptide (GRP) to mouse colon cancer (MC-26) cells. MC-26 cells were inoculated into male BALB/c mice subdermally, and tumors were harvested from mice 21-28 days postinoculation. Tumor membranes were analyzed for binding to GRP-related peptides, using either 125I-GRP or 125I-tyrosine4-BBS. Under optimal binding assay conditions, BBS displaced specific binding of both 125I-GRP and 125I-tyrosine4-BBS in a dose-dependent manner, and a curvilinear displacement resulted. Specific binding data, analyzed by either a Scatchard or a Lineweaver-Burk plot, demonstrated presence of 2 classes of specific binding sites, arbitrarily named type I and type II sites. Type I sites had a high binding affinity [Kd 0.45 ± 0.05 nM (SE)] and a relatively low capacity (226 ± 27 fmol/mg membrane protein), whereas type II sites had a 10-20-fold lower binding affinity and ∼6-7-fold higher capacity. BBS/GRP binding sites were specific for GRP-related peptides and demonstrated no significant binding affinity for all other unrelated peptides tested. Relative binding affinity of GRP analogues was in the order of GRP (14-27) > neuromedin C ≥ BBS ≥ GRP (1-27) > neuromedin B (for the later, P > 0.05 versus other peptides). Two BBS receptor antagonists, [D-Arg1,D-trp7,9,Leu11]-substance P (spantide) and [Leu13-φ-(CH2NH)Leu14]BBS also inhibited specific binding of 125I-GRP in a dose-dependent manner. Molecular weight of GRP/BBS binding proteins on tumor membranes was determined by cross-linking methods. A major molecular form (>80-90%) (Mr ∼75,000) and a minor Mr ∼180,000 band were evident, both under reducing and nonreducing conditions. BBS (0.5-50 nM) demonstrated a significant dose-dependent growth effect on MC-26 cells in vitro, in terms of [3H]thymidine and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide uptake; these studies indicate that the BBS/GRP binding sites on MC-26 cells may serve as functional receptors and mediate the growth effects of BBS on MC-26 cells.

Original languageEnglish (US)
Pages (from-to)6772-6778
Number of pages7
JournalCancer Research
Volume50
Issue number21
StatePublished - Nov 1 1990

Fingerprint

Gastrin-Releasing Peptide
Bombesin
Colonic Neoplasms
Peptides
Growth
Binding Sites
In Vitro Techniques
Bombesin Receptors
Neoplasms
Membranes
Substance P
Thymidine
Carrier Proteins
Membrane Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro. / Narayan, Satya; Guo, Yan Shi; Townsend, Courtney; Singh, Pomila.

In: Cancer Research, Vol. 50, No. 21, 01.11.1990, p. 6772-6778.

Research output: Contribution to journalArticle

@article{a38aed053a2e471d9f83e85cd74343ee,
title = "Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro",
abstract = "In the present study, we characterized specific binding of bombesin (BBS)/gastrin-releasing peptide (GRP) to mouse colon cancer (MC-26) cells. MC-26 cells were inoculated into male BALB/c mice subdermally, and tumors were harvested from mice 21-28 days postinoculation. Tumor membranes were analyzed for binding to GRP-related peptides, using either 125I-GRP or 125I-tyrosine4-BBS. Under optimal binding assay conditions, BBS displaced specific binding of both 125I-GRP and 125I-tyrosine4-BBS in a dose-dependent manner, and a curvilinear displacement resulted. Specific binding data, analyzed by either a Scatchard or a Lineweaver-Burk plot, demonstrated presence of 2 classes of specific binding sites, arbitrarily named type I and type II sites. Type I sites had a high binding affinity [Kd 0.45 ± 0.05 nM (SE)] and a relatively low capacity (226 ± 27 fmol/mg membrane protein), whereas type II sites had a 10-20-fold lower binding affinity and ∼6-7-fold higher capacity. BBS/GRP binding sites were specific for GRP-related peptides and demonstrated no significant binding affinity for all other unrelated peptides tested. Relative binding affinity of GRP analogues was in the order of GRP (14-27) > neuromedin C ≥ BBS ≥ GRP (1-27) > neuromedin B (for the later, P > 0.05 versus other peptides). Two BBS receptor antagonists, [D-Arg1,D-trp7,9,Leu11]-substance P (spantide) and [Leu13-φ-(CH2NH)Leu14]BBS also inhibited specific binding of 125I-GRP in a dose-dependent manner. Molecular weight of GRP/BBS binding proteins on tumor membranes was determined by cross-linking methods. A major molecular form (>80-90{\%}) (Mr ∼75,000) and a minor Mr ∼180,000 band were evident, both under reducing and nonreducing conditions. BBS (0.5-50 nM) demonstrated a significant dose-dependent growth effect on MC-26 cells in vitro, in terms of [3H]thymidine and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide uptake; these studies indicate that the BBS/GRP binding sites on MC-26 cells may serve as functional receptors and mediate the growth effects of BBS on MC-26 cells.",
author = "Satya Narayan and Guo, {Yan Shi} and Courtney Townsend and Pomila Singh",
year = "1990",
month = "11",
day = "1",
language = "English (US)",
volume = "50",
pages = "6772--6778",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro

AU - Narayan, Satya

AU - Guo, Yan Shi

AU - Townsend, Courtney

AU - Singh, Pomila

PY - 1990/11/1

Y1 - 1990/11/1

N2 - In the present study, we characterized specific binding of bombesin (BBS)/gastrin-releasing peptide (GRP) to mouse colon cancer (MC-26) cells. MC-26 cells were inoculated into male BALB/c mice subdermally, and tumors were harvested from mice 21-28 days postinoculation. Tumor membranes were analyzed for binding to GRP-related peptides, using either 125I-GRP or 125I-tyrosine4-BBS. Under optimal binding assay conditions, BBS displaced specific binding of both 125I-GRP and 125I-tyrosine4-BBS in a dose-dependent manner, and a curvilinear displacement resulted. Specific binding data, analyzed by either a Scatchard or a Lineweaver-Burk plot, demonstrated presence of 2 classes of specific binding sites, arbitrarily named type I and type II sites. Type I sites had a high binding affinity [Kd 0.45 ± 0.05 nM (SE)] and a relatively low capacity (226 ± 27 fmol/mg membrane protein), whereas type II sites had a 10-20-fold lower binding affinity and ∼6-7-fold higher capacity. BBS/GRP binding sites were specific for GRP-related peptides and demonstrated no significant binding affinity for all other unrelated peptides tested. Relative binding affinity of GRP analogues was in the order of GRP (14-27) > neuromedin C ≥ BBS ≥ GRP (1-27) > neuromedin B (for the later, P > 0.05 versus other peptides). Two BBS receptor antagonists, [D-Arg1,D-trp7,9,Leu11]-substance P (spantide) and [Leu13-φ-(CH2NH)Leu14]BBS also inhibited specific binding of 125I-GRP in a dose-dependent manner. Molecular weight of GRP/BBS binding proteins on tumor membranes was determined by cross-linking methods. A major molecular form (>80-90%) (Mr ∼75,000) and a minor Mr ∼180,000 band were evident, both under reducing and nonreducing conditions. BBS (0.5-50 nM) demonstrated a significant dose-dependent growth effect on MC-26 cells in vitro, in terms of [3H]thymidine and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide uptake; these studies indicate that the BBS/GRP binding sites on MC-26 cells may serve as functional receptors and mediate the growth effects of BBS on MC-26 cells.

AB - In the present study, we characterized specific binding of bombesin (BBS)/gastrin-releasing peptide (GRP) to mouse colon cancer (MC-26) cells. MC-26 cells were inoculated into male BALB/c mice subdermally, and tumors were harvested from mice 21-28 days postinoculation. Tumor membranes were analyzed for binding to GRP-related peptides, using either 125I-GRP or 125I-tyrosine4-BBS. Under optimal binding assay conditions, BBS displaced specific binding of both 125I-GRP and 125I-tyrosine4-BBS in a dose-dependent manner, and a curvilinear displacement resulted. Specific binding data, analyzed by either a Scatchard or a Lineweaver-Burk plot, demonstrated presence of 2 classes of specific binding sites, arbitrarily named type I and type II sites. Type I sites had a high binding affinity [Kd 0.45 ± 0.05 nM (SE)] and a relatively low capacity (226 ± 27 fmol/mg membrane protein), whereas type II sites had a 10-20-fold lower binding affinity and ∼6-7-fold higher capacity. BBS/GRP binding sites were specific for GRP-related peptides and demonstrated no significant binding affinity for all other unrelated peptides tested. Relative binding affinity of GRP analogues was in the order of GRP (14-27) > neuromedin C ≥ BBS ≥ GRP (1-27) > neuromedin B (for the later, P > 0.05 versus other peptides). Two BBS receptor antagonists, [D-Arg1,D-trp7,9,Leu11]-substance P (spantide) and [Leu13-φ-(CH2NH)Leu14]BBS also inhibited specific binding of 125I-GRP in a dose-dependent manner. Molecular weight of GRP/BBS binding proteins on tumor membranes was determined by cross-linking methods. A major molecular form (>80-90%) (Mr ∼75,000) and a minor Mr ∼180,000 band were evident, both under reducing and nonreducing conditions. BBS (0.5-50 nM) demonstrated a significant dose-dependent growth effect on MC-26 cells in vitro, in terms of [3H]thymidine and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide uptake; these studies indicate that the BBS/GRP binding sites on MC-26 cells may serve as functional receptors and mediate the growth effects of BBS on MC-26 cells.

UR - http://www.scopus.com/inward/record.url?scp=0025028814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025028814&partnerID=8YFLogxK

M3 - Article

C2 - 2208141

AN - SCOPUS:0025028814

VL - 50

SP - 6772

EP - 6778

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 21

ER -